论文部分内容阅读
目的:评价3种抗癌药物(5-Fu、多西他赛、奥沙利铂)联用对晚期胃癌患者的疗效和安全性。方法:选取2013年1月—2015年1月间接受治疗的晚期胃癌患者30例为研究对象,将其分为对照组和治疗组,每组15例;对照组患者均给予多西他赛治疗,治疗组患者均给予多西他赛、奥沙利铂和5-Fu联用方案治疗;评价两组患者治疗后的总有效率以及安全性。结果:治疗组患者治疗后的总有效率为86.66%高于对照组为53.33%(P<0.05);不良反应的发生率相接近其差异无统计学意义(P>0.05)。结论:采用3种抗癌药物(5-Fu、多西他赛、奥沙利铂)治疗晚期胃癌患者的疗效优于单一多西他赛的疗效,其不良反应的发生率之间经比较其差异无统计学意义。
OBJECTIVE: To evaluate the efficacy and safety of three anticancer drugs (5-Fu, docetaxel, oxaliplatin) in patients with advanced gastric cancer. Methods: Thirty patients with advanced gastric cancer who were treated between January 2013 and January 2015 were selected as study subjects and divided into control group and treatment group, 15 cases in each group. Patients in control group were given docetaxel , The treatment group were given docetaxel, oxaliplatin and 5-Fu combined with the program treatment; evaluation of the two groups of patients after treatment, the total efficiency and safety. Results: The total effective rate of the treatment group after treatment was 86.66% higher than that of the control group (53.33%) (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions: The efficacy of 3 anticancer drugs (5-Fu, docetaxel, oxaliplatin) in the treatment of patients with advanced gastric cancer is superior to that of docetaxel alone. The incidence of adverse reactions was compared The difference was not statistically significant.